NCT00453791 - The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2006

Primary Completion Date

April 10, 2006

Study Completion Date

April 10, 2006

Conditions

Asthma

Interventions

DRUG

GW805858

GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.

DRUG

Placebo

Placebo MDI will be given to the subjects.

Trial Locations (1)

SW20 0NE

GSK Investigational Site, London